The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?

Cancer Clin Trials. 1981 Winter;4(4):363-9.

Abstract

The utility of adjuvant CMF in the treatment of breast cancer has been reanalyzed. The actual percentage of patients who benefit from adjuvant CMF has been shown to be relatively small. The widespread use of adjuvant CMF must be further examined.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Axilla
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Breast Neoplasms / surgery
  • Clinical Trials as Topic
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / adverse effects
  • Fluorouracil / therapeutic use*
  • Humans
  • Lymphatic Metastasis
  • Menopause
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use*

Substances

  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate